Patent intelligence · US
US 8106160
N-terminal modified interferon-alpha
N-terminal modified interferon-alpha
Patent details — US 8106160
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 31, 2012
- Expiration
- Jan 26, 2032
- Applicant
- PHARMAESSENTIA CORPORATION
- Claims
- 2
- CPC classes
- A61K, A61K38/00, A61P, A61P31/12
Quick answer
US 8106160 (N-terminal modified interferon-alpha) is held by PHARMAESSENTIA CORPORATION. Status: granted. Granted Jan 31, 2012. Expires Jan 26, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PHARMAESSENTIA CORPORATION
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K38/00, A61P, A61P31/12
More from PHARMAESSENTIA CORPORATION
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 8106160?
US 8106160 (N-terminal modified interferon-alpha) is held by PHARMAESSENTIA CORPORATION. Status: granted. Granted Jan 31, 2012. Expires Jan 26, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8106160?
PHARMAESSENTIA CORPORATION is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 8106160 expire?
Our index shows an expiration date of Jan 26, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.